Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | GJB2 | P29033 | 4/20 | 0.33 |
| ▸ | PYGB | P11216 | 3/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594966 | 1.00 | CA2 (0.35) | CA2SELPSPHK2AMDHD2FBP1 | |
| SCHEMBL14231358 | 1.00 | CA2 (0.35) | CA2SELPSPHK2AMDHD2FBP1 | |
| SCHEMBL10138503 | 0.96 | SELP (0.38) | CA2SELPSPHK2AMDHD2FBP1 | |
| SCHEMBL10138504 | 0.86 | CA2 (0.44) | CA2GJB2GAA | |
| SCHEMBL17848806 | 0.86 | ALDH1A1 (0.46) | SELPSPHK2GJB2TLR4 | |
| SCHEMBL17848795 | 0.86 | ALDH1A1 (0.46) | SELPSPHK2GJB2TLR4 | |
| SCHEMBL17848813 | 0.86 | ALDH1A1 (0.46) | SELPSPHK2GJB2TLR4 | |
| SCHEMBL30610704 | 0.84 | CA2 (0.36) | CA2SELPAMDHD2FBP1PYGB | |
| SCHEMBL26448837 | 0.84 | CA2 (0.36) | CA2SELPAMDHD2FBP1PYGB | |
| SCHEMBL20932845 | 0.83 | FBP1 (0.36) | CA2SELPAMDHD2FBP1PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
| EP-1797192-A1 | MODIFIED PROTEINS | Novo Nordisk Health Care AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035057-A1 | MODIFIED PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | CA2 4529/4885SELP 578/4885SPHK2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.